Macular degeneration: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,019 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06961370· Hoffmann-La Roche· Updated 4 Nov 2026

  “The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.”Registry text, quoted unchanged. Source

• Withdrawn

  Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration

  NCT05780931· VA Office of Research and Development· Updated 5 Oct 2026

  “I was instructed to stop the study, because the underlying VA grant has run out of funds.”Registry text, quoted unchanged. Source

• Terminated

  Study of New Mutations in Cone Disorders

  NCT04658251· University Hospital, Lille· Updated 22 May 2026

  “End of COVID”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of the SING IMT in an Israeli Cohort

  NCT05941273· VisionCare, Inc.· Updated 18 May 2026

  “This decision is driven by the sponsor's strategic considerations.”Registry text, quoted unchanged. Source

• Terminated

  FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

  NCT03846193· Gyroscope Therapeutics Limited· Updated 28 Jan 2026

  “The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.”Registry text, quoted unchanged. Source

• Terminated

  HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04566445· Gyroscope Therapeutics Limited· Updated 28 Jan 2026

  “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”Registry text, quoted unchanged. Source

• Terminated

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Gyroscope Therapeutics Limited· Updated 27 Jan 2026

  “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

  NCT05893537· Cognition Therapeutics· Updated 16 Apr 2025

  “The trial was closed as part of a strategic business decision.”Registry text, quoted unchanged. Source

• Terminated

  Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study

  NCT05200624· Center for Eye Research Australia· Updated 15 Apr 2025

  “Difficulty with meeting recruitment targets”Registry text, quoted unchanged. Source

• Terminated

  Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

  NCT04764656· Novartis Pharmaceuticals· Updated 25 Mar 2025

  “The study was terminated earlier since the obtained sample was not representative of the Portuguese population, and pointed to the high fragility in evaluating the data, making it difficult to carry out a statistical study and draw valid conclusions.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Hoffmann-La Roche· Source

• Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

  NCT07084883· iHealthScreen Inc· Source

• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Regeneron Pharmaceuticals· Source

• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Janssen Research & Development, LLC· Source

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Genentech, Inc.· Source

• Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Ocugen· Source

• Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss

  NCT07216924· University of Minnesota· Source

• A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Hoffmann-La Roche· Source

• Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· AbbVie· Source

• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Apellis Pharmaceuticals, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 25
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 23

• A multi-label deep learning system for simultaneous detection of nine fundus conditions.

  Asia Pac J Ophthalmol (Phila), Sept 2026

• Emerging research trends in the application of artificial intelligence, LLMs, machine learning, and deep learning in ophthalmic diseases: A bibliometric and visual analysis.

  Photodiagnosis Photodyn Ther, Aug 2026

• An AI-Based OCT System to Detect Diabetic Macular Edema: A Prospective Validation and Noninferiority Randomized Clinical Trial.

  JAMA, Jul 2026

• A lightweight DeepME model based on improved YOLOv11 architecture for macular edema detection and treatment monitoring.

  Front Endocrinol (Lausanne), Jul 2026

• Dual branch fundus deep learning network as an enhanced multi classification system for ocular disease detection via hybrid feature fusion.

  Sci Rep, Jul 2026

• Performance of Deep Learning in Classifying Age-Related Macular Degeneration From Images: Systematic Review and Meta-Analysis.

  J Med Internet Res, Jun 2026

• Automated Identification and Segmentation of Diabetic Macular Edema Subtypes Using Deep Learning.

  Transl Vis Sci Technol, Jun 2026

• Macula- Versus Disc-Centered Fundus Photography: Performance in Age-Prediction and Disease Associations.

  Invest Ophthalmol Vis Sci, Jun 2026

• UveAI: clinic-ready scoring of retinal inflammation in uveitis on widefield fluorescein angiography using AI.

  Sci Rep, May 2026

• Multimodal deep learning prediction of treatment response to anti-vascular endothelial growth factor in diabetic macular oedema.

  Eye (Lond), May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.